Drug Trial Radar · NCT01336023
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Feb 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,663
Actual
Start
May 23, 2011
Primary completion
May 24, 2012
Study completion Nov 22, 2012
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Apr 15, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutideDrug
Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
insulin degludecDrug
Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
liraglutideDrug
Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.Time frame: Week 0, week 26
Locations
302 sites in 20 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Anaheim, California
Novo Nordisk Investigational Site
Bermuda Dunes, California
Novo Nordisk Investigational Site
Concord, California
Novo Nordisk Investigational Site
Encino, California
Novo Nordisk Investigational Site
Fair Oaks, California
Novo Nordisk Investigational Site
Fresno, California
Novo Nordisk Investigational Site
Greenbrae, California
Novo Nordisk Investigational Site
La Jolla, California
Novo Nordisk Investigational Site
Long Beach, California
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Montclair, California
Novo Nordisk Investigational Site
Monterey, California
Novo Nordisk Investigational Site
Orange, California
Novo Nordisk Investigational Site
Poway, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Mateo, California
Novo Nordisk Investigational Site
Santa Barbara, California
Novo Nordisk Investigational Site
Tustin, California
Novo Nordisk Investigational Site
Valencia, California
Novo Nordisk Investigational Site
Walnut Creek, California
Novo Nordisk Investigational Site
Colorado Springs, Colorado
Novo Nordisk Investigational Site
Denver, Colorado
Novo Nordisk Investigational Site
Golden, Colorado
Novo Nordisk Investigational Site
Waterbury, Connecticut
Novo Nordisk Investigational Site
Newark, Delaware
Novo Nordisk Investigational Site
Clearwater, Florida
Novo Nordisk Investigational Site
Delray Beach, Florida
Novo Nordisk Investigational Site
Fort Lauderdale, Florida
Novo Nordisk Investigational Site
Hialeah, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Kissimmee, Florida
Novo Nordisk Investigational Site
Melbourne, Florida
Novo Nordisk Investigational Site
Miami, Florida
Novo Nordisk Investigational Site
Miami, Florida
Novo Nordisk Investigational Site
Orlando, Florida
Novo Nordisk Investigational Site
Pembroke Pines, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Showing 40 of 302 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.